tetano
Editor, Senior Moderator
IDCases
. 2021 Nov 17;26:e01343.
doi: 10.1016/j.idcr.2021.e01343. Online ahead of print.
Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019
Satoshi Ide[SUP] 1 2 [/SUP], Sho Saito[SUP] 1 2 [/SUP], Tsubasa Akazawa[SUP] 3 [/SUP], Takahito Furuya[SUP] 3 [/SUP], Junichi Masuda[SUP] 3 [/SUP], Maki Nagashima[SUP] 1 [/SUP], Yusuke Asai[SUP] 4 [/SUP], Tatsunori Ogawa[SUP] 5 [/SUP], Ryohei Yamamoto[SUP] 6 [/SUP], Haruhiko Ishioka[SUP] 7 [/SUP], Kohei Kanda[SUP] 1 [/SUP], Ayako Okuhama[SUP] 1 [/SUP], Yuji Wakimoto[SUP] 1 [/SUP], Tetsuya Suzuki[SUP] 1 2 [/SUP], Yutaro Akiyama[SUP] 1 [/SUP], Yusuke Miyazato[SUP] 1 [/SUP], Keiji Nakamura[SUP] 1 [/SUP], Takato Nakamoto[SUP] 1 [/SUP], Hidetoshi Nomoto[SUP] 1 2 [/SUP], Yuki Moriyama[SUP] 1 2 [/SUP], Masayuki Ota[SUP] 1 [/SUP], Shinichiro Morioka[SUP] 1 2 [/SUP], Wataru Matsuda[SUP] 8 [/SUP], Tatsuki Uemura[SUP] 8 [/SUP], Kentaro Kobayashi[SUP] 8 [/SUP], Ryo Sasaki[SUP] 8 [/SUP], Daisuke Katagiri[SUP] 9 [/SUP], Satoshi Kutsuna[SUP] 1 [/SUP], Kayoko Hayakawa[SUP] 1 [/SUP], Norio Ohmagari[SUP] 1 2 [/SUP]
Affiliations
Abstract
Remdesivir is an antiviral drug that results in clinical improvement after five days of treatment and accelerates recovery by 31%. No studies have discussed the pharmacokinetic analysis of remdesivir in patients with severe COVID-19 requiring extracorporeal membrane oxygenation (ECMO). A 63-year-old American man who underwent mechanical ventilation and ECMO for severe COVID-19 was administered remdesivir for ten days. The loading dosage was 200 mg at 7 PM on day 12 and 100 mg daily at 0:00 PM from day 13 to 21, administered within 1 h. The pharmacokinetic analysis was performed. The serum creatinine concentration was within the normal range of 0.5-0.7 mg/dL during treatment. According to the pharmacokinetic analysis, the plasma concentrations of remdesivir and GS-441524 4 h after administration (C[SUB]4[/SUB]) were 662 ng/mL and 58 ng/mL, respectively, and the concentrations 18 h after administration (C[SUB]18[/SUB]) were 32 ng/mL and 44 ng/mL, respectively. Therefore, the half-life of remdesivir and GS-441524 was 3.2 and 35.1 h, respectively. Monitoring the plasma concentrations of remdesivir and GS-441524 in patients undergoing ECMO may be necessary.
Keywords: extracorporeal membrane oxygenation; pharmacokinetics analysis; remdesivir; severe COVID-19.
. 2021 Nov 17;26:e01343.
doi: 10.1016/j.idcr.2021.e01343. Online ahead of print.
Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019
Satoshi Ide[SUP] 1 2 [/SUP], Sho Saito[SUP] 1 2 [/SUP], Tsubasa Akazawa[SUP] 3 [/SUP], Takahito Furuya[SUP] 3 [/SUP], Junichi Masuda[SUP] 3 [/SUP], Maki Nagashima[SUP] 1 [/SUP], Yusuke Asai[SUP] 4 [/SUP], Tatsunori Ogawa[SUP] 5 [/SUP], Ryohei Yamamoto[SUP] 6 [/SUP], Haruhiko Ishioka[SUP] 7 [/SUP], Kohei Kanda[SUP] 1 [/SUP], Ayako Okuhama[SUP] 1 [/SUP], Yuji Wakimoto[SUP] 1 [/SUP], Tetsuya Suzuki[SUP] 1 2 [/SUP], Yutaro Akiyama[SUP] 1 [/SUP], Yusuke Miyazato[SUP] 1 [/SUP], Keiji Nakamura[SUP] 1 [/SUP], Takato Nakamoto[SUP] 1 [/SUP], Hidetoshi Nomoto[SUP] 1 2 [/SUP], Yuki Moriyama[SUP] 1 2 [/SUP], Masayuki Ota[SUP] 1 [/SUP], Shinichiro Morioka[SUP] 1 2 [/SUP], Wataru Matsuda[SUP] 8 [/SUP], Tatsuki Uemura[SUP] 8 [/SUP], Kentaro Kobayashi[SUP] 8 [/SUP], Ryo Sasaki[SUP] 8 [/SUP], Daisuke Katagiri[SUP] 9 [/SUP], Satoshi Kutsuna[SUP] 1 [/SUP], Kayoko Hayakawa[SUP] 1 [/SUP], Norio Ohmagari[SUP] 1 2 [/SUP]
Affiliations
- PMID: 34804800
- PMCID: PMC8596653
- DOI: 10.1016/j.idcr.2021.e01343
Abstract
Remdesivir is an antiviral drug that results in clinical improvement after five days of treatment and accelerates recovery by 31%. No studies have discussed the pharmacokinetic analysis of remdesivir in patients with severe COVID-19 requiring extracorporeal membrane oxygenation (ECMO). A 63-year-old American man who underwent mechanical ventilation and ECMO for severe COVID-19 was administered remdesivir for ten days. The loading dosage was 200 mg at 7 PM on day 12 and 100 mg daily at 0:00 PM from day 13 to 21, administered within 1 h. The pharmacokinetic analysis was performed. The serum creatinine concentration was within the normal range of 0.5-0.7 mg/dL during treatment. According to the pharmacokinetic analysis, the plasma concentrations of remdesivir and GS-441524 4 h after administration (C[SUB]4[/SUB]) were 662 ng/mL and 58 ng/mL, respectively, and the concentrations 18 h after administration (C[SUB]18[/SUB]) were 32 ng/mL and 44 ng/mL, respectively. Therefore, the half-life of remdesivir and GS-441524 was 3.2 and 35.1 h, respectively. Monitoring the plasma concentrations of remdesivir and GS-441524 in patients undergoing ECMO may be necessary.
Keywords: extracorporeal membrane oxygenation; pharmacokinetics analysis; remdesivir; severe COVID-19.